Tuberculosis Diagnostics Market Size & Growth Forecast 2027–2036, By Segments (Type, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Tuberculosis Diagnostics Market size stood at USD 2.5 billion in 2026 and is predicted to grow at a 5.51% CAGR from 2027 to 2036, attaining USD 4.27 billion by 2036. The industry revenue for 2027 is assessed at USD 2.62 billion.

• Base Year Value (2026): USD 2.5 billion
• CAGR (2027-2036): 5.51%
• Forecast Year Value (2036): USD 4.27 billion
• Historical Data Period: 2022-2026
• Largest Region: Asia Pacific
• Forecast Period: 2027-2036

Tuberculosis Diagnostics Market Intelligence Snapshot:

• Regional Market Dynamics:

  • Asia Pacific leads the market due to its high tuberculosis burden, sustained testing demand, and broad diagnostic deployment across hospitals, public health programs, and community screening initiatives.
  • North America is projected to expand at a 6.89% CAGR, supported by growing adoption of advanced diagnostic technologies and increasing demand for rapid, accurate testing in clinical workflows.

• Segment Momentum:

  • Detection of Latent Infection accounted for 43.03% of the market in 2026, driven by its important role in screening at-risk populations and supporting early intervention before active disease develops.
  • Hospitals & Clinics are the fastest-growing end-use segment because they enable quicker testing, diagnosis, and treatment decisions closer to patient care, supporting more timely intervention and case management.

• Market Expansion Drivers:

  • Rising tuberculosis incidence increasing demand for rapid and accurate diagnostic testing.
  • Expanded global funding programs accelerating tuberculosis screening and diagnostic infrastructure deployment.
  • Growing adoption of molecular drug-resistance testing improving multidrug-resistant tuberculosis detection capabilities.

• Leading Market Participants:

  Major players in the tuberculosis diagnostics market include F. Hoffmann-La Roche AG (Switzerland), Abbott Laboratories (United States), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (United States), Becton, Dickinson and Company (United States), Cepheid, Inc. (United States), Hologic, Inc. (United States), DiaSorin S.p.A. (Italy), Hain Lifescience GmbH (Germany), SD Biosensor, Inc. (South Korea).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 2.5 billion
  • 2027 Estimated Market Size: USD 2.62 billion.
  • Projected Market Size: USD 4.27 billion by 2036
  • Growth Forecasts: 5.51% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: Asia Pacific
  • High-Growth Regional Hub: North America
  • Core Revenue Segment: Detection of Latent Infection (Skin Test & IGRA) (Type) | Diagnostic Laboratories (End-use)
  • Emerging Opportunity Segment: Detection of Drug Resistance (DST) (Type) | Hospitals & Clinics (End-use)

Market Growth Drivers and Industry Trends

Rising tuberculosis incidence increasing demand for rapid and accurate diagnostic testing

The tuberculosis diagnostics market growth is closely associated with the need to identify infections promptly as tuberculosis continues to create a significant diagnostic burden. Rising incidence increases the requirement for testing that can distinguish infected individuals efficiently and support timely clinical decision-making. Greater emphasis on rapid and accurate diagnosis also helps healthcare providers initiate appropriate treatment pathways sooner, while improving the identification of cases that might otherwise remain undetected.

Expanded global funding programs accelerating tuberculosis screening and diagnostic infrastructure deployment

Increased funding for tuberculosis control is strengthening the tuberculosis diagnostics market by enabling healthcare systems to expand screening programs, laboratory capacity, and diagnostic infrastructure. Financial support can facilitate the procurement of testing technologies, establishment of diagnostic facilities, and broader implementation of screening initiatives across populations with elevated disease risk. Improved infrastructure also supports more systematic case identification and strengthens the integration of diagnostic services into national and regional tuberculosis control efforts.

Growing adoption of molecular drug-resistance testing improving multidrug-resistant tuberculosis detection capabilities

Greater use of molecular methods is driving the tuberculosis diagnostics market growth by improving the ability of healthcare providers to identify drug-resistant infections more efficiently. Molecular drug-resistance testing can detect resistance-associated characteristics alongside tuberculosis infection, providing clinically relevant information for cases where conventional approaches may not deliver results as rapidly. Improved identification of multidrug-resistant tuberculosis supports more informed treatment selection and strengthens diagnostic capabilities within programs focused on controlling resistant disease.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising tuberculosis incidence increasing demand for rapid and accurate diagnostic testing	2.00%	High	Asia Pacific, Africa	High	Near Term
Expanded global funding programs accelerating tuberculosis screening and diagnostic infrastructure deployment	1.80%	High	North America, Asia Pacific, Africa	High	Mid Term
Growing adoption of molecular drug-resistance testing improving multidrug-resistant tuberculosis detection capabilities	1.50%	Moderate	Asia Pacific, Europe	Emerging	Mid Term

Regional Demand Dynamics

Asia Pacific (Largest Region) vs North America (Fastest-Growing Region)

Asia Pacific held the largest share of the tuberculosis diagnostics market in 2026, reflecting the substantial need for disease detection across densely populated countries and the continued emphasis on strengthening public health infrastructure. The presence of a significant patient population supports sustained demand for screening and diagnostic services, while government-led disease control programs are encouraging earlier identification and improved access to testing. Increasing investment in laboratory capacity and the adoption of more advanced diagnostic technologies are further reinforcing the region's market position.

North America is the fastest-growing region, supported by continued technological advancement in diagnostic platforms and growing demand for accurate and timely detection methods. Strong healthcare infrastructure and increasing adoption of molecular and other advanced testing approaches are contributing to market development. Efforts to improve testing efficiency, support targeted screening among vulnerable populations, and integrate diagnostics into broader infectious disease management programs are also strengthening regional growth prospects.

Key Country Insights

United States

Advanced Molecular Testing

The U.S. tuberculosis diagnostics market emphasizes rapid molecular testing and integrated laboratory workflows that support timely clinical decision-making. Healthcare providers continue adopting automated diagnostic platforms to improve testing efficiency across hospitals and public health laboratories.

Japan

Early Detection Support

Japan focuses on tuberculosis diagnostics that enable early identification through efficient laboratory technologies and targeted screening initiatives. Healthcare facilities increasingly incorporate sensitive diagnostic methods to improve testing consistency across clinical settings.

South Korea

Integrated Diagnostic Networks

South Korea strengthens tuberculosis diagnostics through coordinated laboratory infrastructure and adoption of advanced molecular technologies. Healthcare providers emphasize streamlined testing processes that improve accessibility and operational efficiency across diagnostic centers.

Germany

Laboratory Precision Focus

Germany prioritizes tuberculosis diagnostics with high analytical accuracy and standardized laboratory performance. Diagnostic providers support healthcare institutions with molecular assays and automated workflows that strengthen reliable disease detection and clinical management.

France

Public Health Screening

France supports tuberculosis diagnostics through structured screening programs and expanded laboratory testing capabilities. Diagnostic suppliers focus on dependable assays that complement national disease surveillance and efficient patient management practices.

Italy

Hospital Testing Capacity

Italy prioritizes tuberculosis diagnostics that improve hospital laboratory performance and support timely infectious disease evaluation. Demand centers on accurate molecular and immunological testing solutions that integrate efficiently into established clinical workflows.

Segment Leadership and Growth Trends

 

Type Segment Analysis: Detection of Latent Infection (Skin Test & IGRA) (Largest Segment) vs Detection of Drug Resistance (DST) (Fastest-Growing Segment)

Detection of latent infection (skin test & IGRA) held the largest share of the tuberculosis diagnostics market in 2026 at 43.03%, reflecting the importance of identifying individuals with tuberculosis infection before progression to active disease. Skin testing and interferon-gamma release assays provide established approaches for screening and risk assessment, supporting their use across preventive healthcare and public health programs. Continued emphasis on early identification, disease prevention, and targeted intervention sustains demand for latent infection diagnostics, particularly where tuberculosis control strategies prioritize timely detection.

Detection of drug resistance (DST) is advancing as the fastest-growing diagnostic category as effective tuberculosis management increasingly depends on identifying resistance patterns and selecting appropriate treatment strategies. Drug-resistant tuberculosis creates greater clinical and public health challenges, increasing the need for diagnostic approaches that can guide treatment decisions. Growing emphasis on rapid and reliable resistance identification, together with broader efforts to strengthen tuberculosis control programs, is supporting increased adoption of DST technologies.

End-use Segment Analysis: Diagnostic Laboratories (Largest Segment) vs Hospitals & Clinics (Fastest-Growing Segment)

Diagnostic laboratories accounted for the largest share of the tuberculosis diagnostics market in 2026, supported by their specialized testing capabilities and role in processing tuberculosis diagnostic samples. Laboratories provide access to standardized testing workflows, trained personnel, and diagnostic infrastructure required for reliable disease detection and characterization. Their ability to perform multiple testing approaches and support centralized diagnostic services makes them an important part of tuberculosis screening and disease management programs. Continued demand for accurate laboratory confirmation and diagnostic monitoring reinforces their leading position.

Hospitals & clinics represent the fastest-growing end-use category as healthcare systems increasingly integrate tuberculosis testing into routine clinical evaluation and patient management. These settings enable diagnostic procedures to be performed closer to patients, supporting timely clinical decision-making and treatment initiation. Increasing emphasis on early diagnosis, improved access to testing, and streamlined care pathways is encouraging greater utilization of tuberculosis diagnostic services within hospitals and clinics.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Type	Detection of Latent Infection (Skin Test & IGRA), Phage Assay, Detection of Drug Resistance (DST), Nucleic Acid Testing, Radiographic Method, Cytokine Detection Assay, Others	Detection of Latent Infection (Skin Test & IGRA)	Detection of Drug Resistance (DST)
End-use	Diagnostic Laboratories, Hospitals & Clinics, Others	Diagnostic Laboratories	Hospitals & Clinics

Competitive Landscape and Market Positioning

Prominent players in the tuberculosis diagnostics market:

1. F. Hoffmann-La Roche AG (Switzerland)

2. Abbott Laboratories (United States)

3. QIAGEN N.V. (Netherlands)

4. Thermo Fisher Scientific Inc. (United States)

5. Becton Dickinson and Company (United States)

6. Cepheid Inc. (United States)

7. Hologic Inc. (United States)

8. DiaSorin S.p.A. (Italy)

9. Hain Lifescience GmbH (Germany)

10. SD Biosensor Inc. (South Korea)

The tuberculosis diagnostics market is experiencing continuous advancement through development of faster and more accurate detection technologies. Industry participants are focusing on molecular diagnostic systems and portable testing solutions to improve accessibility and clinical efficiency. Increasing investments in automated testing platforms are also enhancing competitive dynamics within the market.

Industry Development/News

Company Name	Date	Key Development
The Global Fund	Mar-26	The Global Fund faces a critical $5.36 billion funding shortfall following reduced support from major international donors. This financing gap creates substantial risks for the procurement of tuberculosis diagnostic equipment and the sustainability of global infectious disease testing programs, potentially constraining market growth and access to essential diagnostics in low-resource regions.
Co-Diagnostics	Oct-25	Co-Diagnostics has engineered a specialized sample preparation instrument to optimize its point-of-care PCR-based Mycobacterium tuberculosis testing workflow. By simplifying diagnostic procedures and enhancing operational efficiency in decentralized settings, this hardware integration strengthens the company's competitive positioning in the rapid TB testing segment and improves overall diagnostic accessibility at the point of care.
Indian Council of Medical Research (ICMR)	Mar-25	The Indian Council of Medical Research has formally validated a suite of advanced diagnostic tools, including AI-driven chest X-ray analysis, molecular TB assays, and portable X-ray systems. This strategic integration of digital and molecular diagnostics is designed to accelerate screening throughput, enhance detection sensitivity, and expand the reach of TB diagnostic infrastructure across diverse clinical settings.
Revvity, Inc.	Apr-24	Revvity, Inc. integrated the Allsheng Auto-Pure 2400 liquid handler into its workflow for the T-SPOT.TB test. This partnership and technology deployment enhances laboratory automation capabilities, aiming to improve testing productivity and operational efficiency. The integration demonstrates a strategic effort to streamline diagnostic sample processing and strengthen the functional performance of established TB screening platforms in clinical laboratory environments.